Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025)

Caris Life Sciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2025.

• In Q1 2025, Preferred Stock Liabilities changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2025 stood at $2.2 billion (changed N/A YoY), while the FY2024 annual figure was $2.2 billion, up 4.53% from the prior year.
• Preferred Stock Liabilities for Q1 2025 stood at $2.2 billion, up from $2.2 billion in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $2.2 billion in Q1 2025, with the low at $2.2 billion in Q2 2024.